Connetics Hit With Shareholder Lawsuit Over Failed Drug

Law360, New York (September 21, 2006, 12:00 AM EDT) -- Connetics Corp., a pharmaceutical company specializing in dermatological products, has been hit with a securities class action over allegations that it concealed a finding on a new drug which eventually caused the Food and Drug Administration to reject it.

The suit alleges that after a six-month study on mice, Connetics concealed the discovery that 55% of the mice treated with Velac, a new acne medication, developed tumors.

The company also falsified financial reports by failing to properly reserve for rebates, so that it could cash in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.